Skip to main content

Table 1 Summary of FDA-approved IL-6 receptor antagonist

From: Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019

Generic name

Brand name

Indication

Year of approval by FDA

Tocilizumab

Actemra

RA, CRS, sJIA, Giant cell arteritis, COVID-19

2003; tocilizumab was granted an EUA for the treatment of COVID-19 in June 2021

Sarilumab

Kevzara

RA

2017

  1. RA rheumatoid arthritis, CRS cytokine release syndrome, sJIA systemic juvenile idiopathic arthritis